Takeda Globally Signs Licensing, Co-Development & Co-Promotion Agreement with Enterome for its EB8018 Candidate

 Takeda Globally Signs Licensing, Co-Development & Co-Promotion Agreement with Enterome for its EB8018 Candidate

Takeda Globally Signs Licensing, Co-Development & Co-Promotion Agreement with Enterome for its EB8018 Candidate

Shots:

  • Enterome to get $50M upfront plus $640M as milestones payments and future equity investment commitment from Takeda. The companies will jointly co-develop EB8018 and if approved, the product will be co-promoted in the US with equal profit/cost sharing
  • Takeda to get hold of exclusive license rights for EB8018 to commercialize outside the US and give royalties on sales to Enterome
  • EB8018 PO is a novel P-Ib candidate indicated in Crohn’s disease, testing its safety, tolerability, PK & efficacy and has successfully completed its P-Ia

Click here to read full press release/ article | Ref: Enterome Biosciences | Image: Asia Nikkei

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post